LONDON, December 11, 2018 /PRNewswire/ --
Experienced industry
Executive joins investment team to support
portfolio development
Arix Bioscience plc (LSE:ARIX) ("Arix"), a global healthcare and
life science company supporting medical innovation, today announces
the appointment of Dr Christian
Schetter as Entrepreneur in Residence (EIR). Christian has
over 20 years' industry experience across the life sciences sector,
and joins Arix from German immuno-oncology company Rigontec GmbH,
where he was CEO for four years before its acquisition by MSD.
Joe Anderson, Chief
Investment Officer at Arix said: "I am
delighted to welcome Christian to the team. He has a track
record of creating companies that foster
exciting science and securing impressive exits. His
extensive experience of building companies in the life science
industry will greatly benefit Arix as we continue
to build on our existing investments and
leverage our extensive pipeline."
Christian Schetter
commented: "Arix has a varied portfolio of innovative
companies that it is committed to building and developing.
Arix has grown significantly since its IPO and not only built a
diverse portfolio, but also a unique group of industry and academic
partners, and a talented international investment team.
I am very excited to join Arix and look forward to
supporting the team in evolving this pipeline
as we build the next generation of world leading biotech
companies."
Dr Schetter has over 20 years' experience in the life science
industry. In 2017, as CEO of Rigontec GmbH, he led the company to a
successful acquisition by MSD valued at EUR
115m with an additional EUR
349m in potential milestone payments. Prior to his role at
Rigontec GmbH, Christian was President and CEO of Neovii Biotech
(previously Fresenius Biotech). During his tenure, one antibody
product was brought to market and the indication for another
product expanded. Christian was also instrumental in selling
Fresenius Biotech to the Neopharm Group, Israel, to form Neovii Biotech and positioning
it as a successful standalone business. He was SVP of European
Operations at Coley Pharmaceutical Group and Managing Director of
Coley GmbH. Christian was part of the leadership team which built
Coley Pharmaceuticals from inception through multiple financing
rounds, a NASDAQ IPO and, following several significant pharma
deals, to a trade sale to Pfizer in 2007.
Before entering the life science industry, Christian was
successfully performing academic research at the Max Planck
Institute in Martinsried, Germany.
He received his undergraduate degree and PhD from the University of
Cologne and did postdoctoral
research in oncology and virology at the Scripps Research Institute in La Jolla, California.
About Arix Bioscience plc
Arix Bioscience plc is a global healthcare and life science
company supporting medical innovation. Headquartered in
London and with an office in
New York, Arix Bioscience sources,
finances and builds world class healthcare and life science
businesses addressing medical innovation at all stages of
development. Operations are supported by privileged access to
breakthrough academic science and strategic relationships with
leading research accelerators and global pharmaceutical
companies.
Arix Bioscience plc is listed on the Main Market of the London
Stock Exchange.
PRN NLD